Bryan Wahl's most recent trade in Tarsus Pharmaceuticals Inc was a trade of 3,341 Common Stock done at an average price of $46.3 . Disclosure was reported to the exchange on March 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Sale of securities on an exchange or to another person at price $ 46.29 per share. | 18 Mar 2025 | 3,341 | 58,057 | - | 46.3 | 154,655 | Common Stock |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Sale of securities on an exchange or to another person at price $ 47.40 per share. | 18 Mar 2025 | 3,261 | 54,796 | - | 47.4 | 154,571 | Common Stock |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Sale of securities on an exchange or to another person at price $ 50.11 per share. | 18 Mar 2025 | 3,084 | 51,712 | - | 50.1 | 154,539 | Common Stock |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 19,213 | 61,398 | - | - | Common Stock | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 7,248 | 14,497 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 7,175 | 21,527 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2025 | 4,790 | 4,790 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 30,628 | 30,628 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 20,089 | 20,089 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 12,038 | 45,387 | - | - | Common Stock | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 7,248 | 21,745 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2024 | 4,790 | 9,580 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Sale of securities on an exchange or to another person at price $ 30.60 per share. | 15 Mar 2024 | 4,436 | 40,951 | - | 30.6 | 135,742 | Common Stock |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 42,500 | 42,500 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 28,702 | 28,702 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Sale of securities on an exchange or to another person at price $ 12.15 per share. | 21 Mar 2023 | 371 | 16,402 | - | 12.2 | 4,508 | Common Stock |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Sale of securities on an exchange or to another person at price $ 12.64 per share. | 21 Mar 2023 | 357 | 16,773 | - | 12.6 | 4,512 | Common Stock |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Sale of securities on an exchange or to another person at price $ 12.89 per share. | 21 Mar 2023 | 350 | 17,130 | - | 12.9 | 4,512 | Common Stock |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Sale of securities on an exchange or to another person at price $ 12.61 per share. | 17 Mar 2023 | 357 | 17,480 | - | 12.6 | 4,502 | Common Stock |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Sale of securities on an exchange or to another person at price $ 13.28 per share. | 17 Mar 2023 | 339 | 17,837 | - | 13.3 | 4,502 | Common Stock |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2023 | 4,790 | 14,370 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2023 | 4,790 | 18,513 | - | - | Common Stock | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Sale of securities on an exchange or to another person at price $ 13.43 per share. | 15 Mar 2023 | 337 | 18,176 | - | 13.4 | 4,526 | Common Stock |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 42,802 | 42,802 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2023 | 28,993 | 28,993 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Sale of securities on an exchange or to another person at price $ 16.90 per share. | 02 Dec 2022 | 1,154 | 13,723 | - | 16.9 | 19,503 | Common Stock |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2022 | 10,251 | 17,224 | - | 0 | Common Stock | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2022 | 10,251 | 23,920 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Sale of securities on an exchange or to another person at price $ 16.50 per share. | 29 Nov 2022 | 1,183 | 16,041 | - | 16.5 | 19,520 | Common Stock |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Sale of securities on an exchange or to another person at price $ 16.75 per share. | 29 Nov 2022 | 1,164 | 14,877 | - | 16.8 | 19,497 | Common Stock |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 65,312 | 65,312 | - | - | Stock Option (right to buy) | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 34,171 | 34,171 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2022 | 19,160 | 19,160 | - | - | Restricted Stock Units | |
| Tarsus Pharmaceuticals Inc | Bryan Wahl | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2021 | 89,368 | 89,368 | - | - | Stock Option (right to buy) |